A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma

Prior treatment

• Have previously received systemic or local treatment including chemotherapy;
• Previously received autologous stem cell transplantation;
• Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study.

Other illness

• Previous history of other malignant tumors, except skin basal cell carcinoma and cervical carcinoma in situ;
• Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases and serious infectious diseases;
• Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
• Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection (polymerase chain Reaction \[PCR\] showed positive results). If the HbsAg test result is positive, HBV DNA test should be performed, if the HBV DNA\<103IU/ml, can be enrolled. If HBsAg test results are negative, but HBcAb test is positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA\<103 IU/ml can be enrolled. If the patient's HCV antibody is positive, the HCV RNA is detected by PCR. If positive, the exclusion criteria are met.

Lab values

• Left ventricular ejection fraction \< 50%;
• Laboratory test values at the time of screening: (unless due to lymphoma);
  • Neutrophils \< 1.5 x 109/L;
  • Platelet \< 75 x 109/L;
  • ALT or AST were 2 times higher than the upper limit of normal, AKP and bilirubin were 1.5 times higher than the upper limit of normal;
  • creatinine levels higher than 1.5 times the upper limit of normal;

Other

• Lymphoma involves the central nervous system;
• Primary mediastinal large B-cell lymphoma;
• Pregnant or lactating women;

• Initial treatment of diffuse large B-cell lymphoma (DLBCL) confirmed by tumor histopathology with at least one lesion on either axis More than 1.5 cm, sufficient specimens for second-generation sequencing or single-cell sequencing;
• Age \> 18 years old, \< 80 years old, gender unlimited;
• EBER+ or peripheral blood EBV-DNA of pathological specimen was greater than 103copy/ml;
• Patients judged by the investigator to have a life expectancy of at least 6 months;
• The patient or his legal representative must provide written informed consent prior to any research special examination or procedure.
• Signed written informed consent before screening.